Jonathon A Bard

Title: Jonathon A Bard: Innovator in Adrenergic Receptor Research

Introduction

Jonathon A Bard is a notable inventor based in Wyckoff, NJ (US). He has made significant contributions to the field of molecular biology, particularly in the study of adrenergic receptors. His work has implications for understanding various physiological processes and developing therapeutic strategies.

Latest Patents

Jonathon A Bard holds a patent for "DNA encoding human .alpha. 1 adrenergic receptors and uses thereof." This invention provides an isolated nucleic acid, vectors, transformed mammalian cells, and non-human transgenic animals that encode and express normal or mutant .alpha. 1a, .alpha. 1b, and .alpha. 1c adrenergic receptor genes. Additionally, it includes a protein and an antibody directed to the protein, along with pharmaceutical compounds related to these adrenergic receptors. The invention also offers nucleic acid probes and antisense oligonucleotides complementary to the adrenergic receptor genes. Furthermore, it provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human .alpha. 1a, .alpha. 1b, and .alpha. 1c adrenergic receptors.

Career Highlights

Jonathon A Bard is associated with Synaptic Pharmaceutical Corporation, where he has been instrumental in advancing research related to adrenergic receptors. His innovative work has contributed to the understanding of receptor biology and its applications in pharmacology.

Collaborations

Jonathon has collaborated with notable colleagues, including Richard L Weinshank and Carlos C Forray. These collaborations have further enriched his research and expanded the impact of his inventions.

Conclusion

Jonathon A Bard's contributions to the field of adrenergic receptor research exemplify the importance of innovation in biotechnology. His patent and ongoing work continue to pave the way for advancements in medical science and therapeutic development.